PHASE-II EVALUATION OF 4'DEOXYDOXORUBICIN IN ADVANCED RENAL-CELL CARCINOMA

被引：4

作者：

KISH, JA ^{[1
]}

ENSLEY, JF ^{[1
]}

ALSARRAF, M ^{[1
]}

机构：

[1] WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DETROIT,MI 48201

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1990年 / 13卷 / 01期

关键词：

D O I：

10.1097/00000421-199002000-00005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4' Deoxydoxorubicin was evaluated in patients with advanced renal carcinoma. Only one partial remission was noted, and no significant cardiac toxicity was seen on serial evaluation of ejection fractions. Appropriate dose escalations were performed.

引用

页码：17 / 18

页数：2

共 5 条

[1] BERENS ME, 1987, CANCER CHEMOTH PHARM, V19, P301
[2] BRAICH TA, 1986, INVEST NEW DRUG, V4, P269
[3] RICHIE JP, 1982, CANCER KIDNEY, P632
[4] 4'DEOXYDOXORUBICIN IN ADVANCED RENAL-CANCER - A PHASE-II STUDY IN PREVIOUSLY UNTREATED PATIENTS FROM THE EORTC GENITOURINARY TRACT CANCER COOPERATIVE GROUP
VANOOSTEROM, AT
BONO, AV
KAYE, SB
SPLINTER, TAW
CALCIATI, A
FOSSA, SD
DEPAUW, M
SYLVESTER, R
[J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (12): : 1531 - 1532
[5] WEISS RB, 1986, CANCER CHEMOTH PHARM, V18, P185

← 1 →